Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.

Future Med Chem

National Engineering Research Center For The Emergency Drug, Beijing Institute of Pharmacology & Toxicology, Beijing, 100850, China.

Published: September 2020

SARS-CoV-2 has been widely spread around the world and COVID-19 was declared a global pandemic by the WHO. Limited clinically effective antiviral drugs are available now. The development of anti-SARS-CoV-2 drugs has become an urgent work worldwide. At present, potential therapeutic targets and drugs for SARS-CoV-2 are continuously reported, and many repositioning drugs are undergoing extensive clinical research, including remdesivir and chloroquine. On the other hand, structures of many important viral target proteins and host target proteins, including that of RdRp and Mpro were constantly reported, which greatly promoted structure-based drug design. This paper summarizes the current research progress and challenges in the development of anti-SARS-CoV-2 drugs, and proposes novel short-term and long-term drug research strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341957PMC
http://dx.doi.org/10.4155/fmc-2020-0158DOI Listing

Publication Analysis

Top Keywords

repositioning drugs
8
drugs sars-cov-2
8
development anti-sars-cov-2
8
anti-sars-cov-2 drugs
8
target proteins
8
drugs
7
progress repositioning
4
drugs specific
4
specific therapeutic
4
therapeutic drugs
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!